Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

NovaBay announces results of NVC-422 phase 2 for Viral Conjunctivitis


Wednesday, 20 Aug 2014 07:00am EDT 

NovaBay Pharmaceuticals Inc:Says its NVC-422 ophthalmic formulation did not meet the primary or secondary endpoints in a Phase 2 clinical study in patients with adenoviral conjunctivitis.Trial was a global, multi-centered, randomized study that enrolled patients with adenoviral conjunctivitis in the United States, India, Sri Lanka, and Brazil.Endpoints measured clearing of bulbar conjunctival injection (red eye), eradication of adenovirus from the tear film, spread of infection to the fellow eye, reduction in sub-epithelial infiltrates, clearing of blurred vision compared to its Vehicle at Test-of-Cure Visit (Day 18).No significant adverse events were reported in the trial. 

Company Quote

0.7767
0.0067 +0.87%
2:36pm EDT